ReviewImmune network2021
Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages.
Review in Immune network, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects.Frontiers in immunology · 2022Pooled it
- Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Evaluation of the analytical performance of three chemiluminescence serological assays for detecting anti-SARS-CoV-2 antibodies.Clinical and experimental medicine · 2023Article
- Sequential Administration of SARS-CoV-2 Strains-Based Vaccines Effectively Induces Potent Immune Responses against Previously Unexposed Omicron Strain.Pathogens (Basel, Switzerland) · 2023Article
- A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Review
- SARS-CoV-2 spike RBD-specific IgA and IgG antibodies in breast milk after vaccination with the protein subunit vaccine Abdala.Infectious medicine · 2022Article
- Review
- Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin.Vaccines · 2022Article
- Sheet, Surveillance, Strategy, Salvage and Shield in global biodefense system to protect the public health and tackle the incoming pandemics.The Science of the total environment · 2022Review
- Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.Journal of medical virology · 2022Article
- Advanced Materials for SARS-CoV-2 Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2022Review
- Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.Pharmaceutics · 2022Review
- A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: Effects on proteolytic cleavage and ACE2 binding.Immunology letters · 2022Article
- A Comprehensive Review on Various Aspects of SARS-CoV-2 (COVID-19) Vaccines.International journal of preventive medicine · 2022Review
- Scope of SARS-CoV-2 variants, mutations, and vaccine technologies.The Egyptian journal of internal medicine · 2022Review
- Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?Human vaccines & immunotherapeutics · 2021Review
- Review
- Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness.Bioengineering (Basel, Switzerland) · 2021Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global outbreak of coronavirus disease 2019 (COVID-19) is still threatening human health, economy, and social life worldwide. As a counteraction for this devastating disease, a number of vaccines are being developed with unprecedented speed combined with new technologies. As COVID-19 vaccines are being developed in the absence of a licensed human coronavirus vaccine, there remain further questions regarding the long-term efficacy and safety of the vaccines, as well as immunological mechanisms in depth. This review article discusses the current status of COVID-19 vaccine development, mainly focusing on antigen design, clinical trials in later stages, and immunological considerations for further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.